Page 7 - AIH-1-3

Artificial Intelligence in Health

REVIEW ARTICLE
AI and pharma: Transforming the paradigm,

embracing the new era

Harjeevan Singh Kang*
College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

Abstract

This review delves into the dynamic intersection of artificial intelligence (AI)
and the pharmaceutical industry, exploring a wide spectrum of clinical and
commercial applications, challenges and risks, potential solutions, and future
outlooks as these domains converge. With the rapid advancement of AI, this review
addresses the profound implications of AI in the life sciences sector, emphasizing
its potential to revolutionize drug discovery, clinical trials, personalized medicine,
pharmacovigilance, sales, and marketing. While lauding the paradigm-shifting
prospects, this paper confronts the ethical, privacy, and bias risks entwined with
AI development and deployment. Forward-looking solutions, including fortified
data governance frameworks, transparent AI algorithms, and interdisciplinary
alliances, stand as bulwarks against these impediments. Furthermore, it considers
the possibilities afforded to AI by emergent technologies, such as quantum cloud
computing and low-code solutions. In conclusion, this review envisions a future
where AI, in collaboration with innovative technologies, reshapes the pharmaceutical
*Corresponding author: landscape. By promoting informed discussions and collaboration, this review seeks
Harjeevan Singh Kang to empower the industry to harness the transformative potential of AI in an ethical
(harjeevankangmedicine@gmail. manner.
com)
Citation: Kang HS. AI and pharma:
Transforming the paradigm, Keywords: Artificial intelligence; Pharma; Clinical; Marketing; Sales; Regulation
embracing the new era. Artif Intell
Health. 2024;1(3):1-9.
doi: 10.36922/aih.2973
Received: February 20, 2024 1. Introduction
Accepted: March 15, 2024 “The illiterate of the 21 century will not be those who cannot read and write
st
Published Online: May 14, 2024 but those who cannot learn, unlearn, and relearn.” 1
Copyright: © 2024 Author(s). To maintain operations, organizations across various industries were forced to adapt,
This is an Open-Access article embrace change, and innovate in response to the COVID-19 pandemic. This necessity
2
distributed under the terms of the
Creative Commons Attribution to adopt agile working practices is expected to remain pertinent for the foreseeable
License, permitting distribution, future, especially as technology continues to evolve and be integrated as part of the
and reproduction in any medium, digital transformation plans of organizations. 3
provided the original work is
properly cited. The life sciences industry has not been immune to the profound impacts of the global
Publisher’s Note: AccScience pandemic. Pharmaceutical companies have contended with external issues in terms of
Publishing remains neutral with supply chain disruption and inflation, as well as operational and workforce recruitment
regard to jurisdictional claims in 4
published maps and institutional challenges. The pandemic also spurred a shift to remote working, due to lockdowns
affiliations. and social distancing measures, highlighting the need for digital platforms to facilitate

Volume 1 Issue 3 (2024) 1 doi: 10.36922/aih.2973